Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 19Completed 17Recruiting 14Not yet recruiting 12Terminated 3Active not recruiting 2Suspended 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Advanced HER2 Negative Breast Carcinoma HRD+Breast Cancer 1

Interventions

Specimen Handling 32Magnetic Resonance Spectroscopy 21Biopsy 20Cyclophosphamide 16Nivolumab 10Paclitaxel 9Cisplatin 9Gemcitabine 8Bevacizumab 8venetoclax 7Vincristine 7Prednisone 7Doxorubicin 7Azacitidine 7pembrolizumab 6Radiotherapy 6Radiosurgery 6Fluorouracil 6Etoposide 6Drug Therapy 6Docetaxel 6Taxes 5Rituximab 5Oxaliplatin 5Irinotecan 5Everolimus 5Capecitabine 5fludarabine phosphate 4fludarabine 4Surgical Procedures, Operative 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Suspended × Interventional × fluzoparib × Clear all
NCT05656131 2026-03-17

Fluzoparib in Combination With or Without Camrelizumab for Homologous Recombinant Deficiency (HRD) HER2 Negative Advanced Breast Cancer

Sun Yat-sen University

Phase 2 Suspended
80 enrolled
Breast

Advanced HER2 Negative Breast Carcinoma HRD+Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡